ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Biogen, Swedish Orphan Biovitrum and AbbVie side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

Biogen×Swedish Orphan Biovitrum×AbbVie×Three at a time for now; Pro will compare up to ten.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

BiogenSwedish Orphan BiovitrumAbbVie
studies on the registry5491372,251
open to participants now286133
phase 3 studies under way19574
reach primary completion within a year15390
programswith a study of their own in two years11770+8 named only

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseBiogenSwedish Orphan BiovitrumAbbVie
Phase 1

Biogen: 3 of its 11 programs at phase 1

  1. BIIB142phase 1
  2. BIIB144phase 1
  3. BIIB145phase 1
27%
00%

AbbVie: 28 of its 70 programs at phase 1

  1. Anti-CD19-Glucosteroid Receptor Modulator ADC ABBV-31phase 1
  2. surzetoclaxphase 1
  3. BTK Degrader ABBV-101phase 1
  4. ABBV-1162phase 1
  5. ABBV-1451phase 1

and 23 more — sign in to see them all

40%
Phase 2

Biogen: 1 of its 11 programs at phase 2

  1. BIIB147phase 2
9%

Swedish Orphan Biovitrum: 1 of its 7 programs at phase 2

  1. XOI Low Dosephase 2
14%

AbbVie: 20 of its 70 programs at phase 2

  1. ABBV-295phase 2
  2. zumilokibartphase 2
  3. ABBV-932phase 2
  4. trosunilimabphase 2
  5. ABBV-701phase 2

and 15 more — sign in to see them all

29%
Phase 3

Biogen: 5 of its 11 programs at phase 3

  1. felzartamabphase 3
  2. pegcetacoplanphase 3
  3. salanersenphase 3
  4. omaveloxolonephase 3
  5. diroximel fumaratephase 3
45%

Swedish Orphan Biovitrum: 2 of its 7 programs at phase 3

  1. pacritinibphase 3
  2. AR882phase 3
29%

AbbVie: 16 of its 70 programs at phase 3

  1. telisotuzumab adizutecanphase 3
  2. etentamigphase 3
  3. lutikizumabphase 3
  4. mirvetuximab soravtansinephase 3
  5. turmetabart adizutecanphase 3

and 11 more — sign in to see them all

23%
Approved, new studies

Biogen: 2 of its 11 programs at approved, new studies

  1. tofersenapproved, new study
  2. Dimethyl Fumarateapproved, new study
18%

Swedish Orphan Biovitrum: 4 of its 7 programs at approved, new studies

  1. efanesoctocog alfaapproved, new study
  2. pegcetacoplanapproved, new study
  3. avatrombopagapproved, new study
  4. Interleukin 1 Receptor Antagonist Proteinapproved, new study
57%

AbbVie: 6 of its 70 programs at approved, new studies

  1. upadacitinibapproved, new study
  2. risankizumabapproved, new study
  3. venetoclaxapproved, new study
  4. botulinum toxin type Aapproved, new study
  5. atogepantapproved, new study

and 1 more — sign in to see them all

9%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Biogen4 readouts · 2 phase 3·

Biogen, Dec ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. felzartamabphase 3 · Dec 1 · NCT06685757
·

Biogen, Feb ’27: 1 program whose next study reaches primary completion

  1. BIIB145phase 1 · Feb 2 · NCT07225517
··

Biogen, May ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. tofersenapproved, new study · May 26 · NCT07223723

Biogen, Jun ’27: 1 program whose next study reaches primary completion

  1. pegcetacoplanphase 3 · Jun 25 · NCT07215390
····
Swedish Orphan Biovitrum3 readouts · 1 phase 3

Swedish Orphan Biovitrum, Nov ’26: 2 programs whose next study reaches primary completion

  1. AR882phase 3 · Nov 0 · NCT07116746
  2. XOI Low Dosephase 2 · Nov 0 · NCT07116746
···

Swedish Orphan Biovitrum, Mar ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. efanesoctocog alfaapproved, new study · Mar 0 · NCT06716814
·······
AbbVie34 readouts · 5 phase 3

AbbVie, Nov ’26: 6 programs whose next study reaches primary completion, 1 in phase 3

  1. ABBV-701phase 2 · Nov 0 · NCT06895343
  2. ABBV-932phase 2 · Nov 0 · NCT06846320
  3. mirvetuximab soravtansinephase 3 · Nov 0 · NCT05456685
  4. upadacitinibapproved, new study · Nov 0 · NCT06389136
  5. venetoclaxapproved, new study · Nov 0 · NCT04895436

and 1 more — sign in to see them all

AbbVie, Dec ’26: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. ABBV-295phase 2 · Dec 0 · NCT07514260
  2. emraclidinephase 2 · Dec 0 · NCT07219030
  3. lutikizumabphase 3 · Dec 0 · NCT06468228
  4. telisotuzumab adizutecanphase 3 · Dec 0 · NCT06107413

AbbVie, Jan ’27: 1 program whose next study reaches primary completion

  1. risankizumabapproved, new study · Jan 0 · NCT07466550

AbbVie, Feb ’27: 9 programs whose next study reaches primary completion

  1. [11C]ABBV-112iearly phase 1 · Feb 0 · NCT07933497
  2. ABBV-859phase 1 · Feb 0 · NCT07736638
  3. Anti-CD19-Glucosteroid Receptor Modulator ADC ABBV-31phase 1 · Feb 0 · NCT05512390
  4. etentamigphase 3 · Feb 0 · NCT06223516
  5. MEDI0618phase 2 · Feb 0 · NCT06602479

and 4 more — sign in to see them all

·

AbbVie, Apr ’27: 1 program whose next study reaches primary completion

  1. ABBV-1451phase 1 · Apr 0 · NCT07570147

AbbVie, May ’27: 6 programs whose next study reaches primary completion, 1 in phase 3

  1. ABBV-1162phase 1 · May 0 · NCT07832708
  2. ABBV-243phase 1 · May 0 · NCT07306754
  3. ABBV-7828phase 1 · May 0 · NCT07856706
  4. Anti-PSMA/STEAP1 Antibody-drug Conjugate ABBV-969phase 1 · May 0 · NCT06318273
  5. trosunilimabphase 2 · May 0 · NCT07925983

and 1 more — sign in to see them all

AbbVie, Jun ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. botulinum toxin type Aapproved, new study · Jun 0 · NCT07794891

AbbVie, Jul ’27: 4 programs whose next study reaches primary completion

  1. ABBV-1606phase 1 · Jul 0 · NCT07935564
  2. azirkitugphase 1 · Jul 0 · NCT05005403
  3. surzetoclaxphase 2 · Jul 0 · NCT06291220
  4. surzetoclaxphase 1 · Jul 0 · NCT06291220

AbbVie, Aug ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. vedolizumabphase 3 · Aug 0 · NCT06880744

AbbVie, Sep ’27: 1 program whose next study reaches primary completion

  1. icalcaprantphase 2 · Sep 0 · NCT07276997
·
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 21, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Biogen

New programs 1

  • BIIB147phase 2 · first study · Sep 28 · Amyotrophic Lateral Sclerosis

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 1

Swedish Orphan Biovitrum

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

AbbVie

New programs 5

Reached a new phase 1

  • ABBV-722phase 3 · Oct 23 · Scleroderma, Systemic

Study stopped 0

None

Primary completion later 10

Where they overlap

Conditions where at least two of them have programs: 13 in all, the first 12 here. A program counts in each condition its studies name most.

ConditionBiogenSwedish Orphan BiovitrumAbbVie
Arthritis, Rheumatoidall three · compare here

Biogen in Arthritis, Rheumatoid: 1 program

  1. Dimethyl Fumarateapproved, new study

Their studies: Biogen’s studies of Arthritis, Rheumatoid in search

Swedish Orphan Biovitrum in Arthritis, Rheumatoid: 1 program

  1. Interleukin 1 Receptor Antagonist Proteinapproved, new study

Their studies: Swedish Orphan Biovitrum’s studies of Arthritis, Rheumatoid in search

AbbVie in Arthritis, Rheumatoid: 5 programs

  1. lutikizumabphase 3
  2. ABBV-722phase 3
  3. ravagalimabphase 2
  4. CPTX2309phase 1
  5. upadacitinibapproved, new study

Their studies: AbbVie’s studies of Arthritis, Rheumatoid in search

Macular Degenerationall three · compare here

Biogen in Macular Degeneration: 1 program

  1. pegcetacoplanphase 3

Their studies: Biogen’s studies of Macular Degeneration in search

Swedish Orphan Biovitrum in Macular Degeneration: 1 program

  1. pegcetacoplanapproved, new study

Their studies: Swedish Orphan Biovitrum’s studies of Macular Degeneration in search

AbbVie in Macular Degeneration: 3 programs

  1. surabgene lomparvovecphase 3
  2. Ranibizumab Controlphase 3
  3. pegcetacoplanphase 2

Their studies: AbbVie’s studies of Macular Degeneration in search

Geographic Atrophyall three · compare here

Biogen in Geographic Atrophy: 1 program

  1. pegcetacoplanphase 3

Their studies: Biogen’s studies of Geographic Atrophy in search

Swedish Orphan Biovitrum in Geographic Atrophy: 1 program

  1. pegcetacoplanapproved, new study

Their studies: Swedish Orphan Biovitrum’s studies of Geographic Atrophy in search

AbbVie in Geographic Atrophy: 2 programs

  1. ABBV-6628phase 2
  2. pegcetacoplanphase 2

Their studies: AbbVie’s studies of Geographic Atrophy in search

Anemia, Hemolytic, Autoimmuneall three · compare here

Biogen in Anemia, Hemolytic, Autoimmune: 1 program

  1. pegcetacoplanphase 3

Their studies: Biogen’s studies of Anemia, Hemolytic, Autoimmune in search

Swedish Orphan Biovitrum in Anemia, Hemolytic, Autoimmune: 1 program

  1. pegcetacoplanapproved, new study

Their studies: Swedish Orphan Biovitrum’s studies of Anemia, Hemolytic, Autoimmune in search

AbbVie in Anemia, Hemolytic, Autoimmune: 1 program

  1. pegcetacoplanphase 2

Their studies: AbbVie’s studies of Anemia, Hemolytic, Autoimmune in search

Glomerulonephritis, Membranoproliferativeall three · compare here

Biogen in Glomerulonephritis, Membranoproliferative: 1 program

  1. pegcetacoplanphase 3

Their studies: Biogen’s studies of Glomerulonephritis, Membranoproliferative in search

Swedish Orphan Biovitrum in Glomerulonephritis, Membranoproliferative: 1 program

  1. pegcetacoplanapproved, new study

Their studies: Swedish Orphan Biovitrum’s studies of Glomerulonephritis, Membranoproliferative in search

AbbVie in Glomerulonephritis, Membranoproliferative: 1 program

  1. pegcetacoplanphase 2

Their studies: AbbVie’s studies of Glomerulonephritis, Membranoproliferative in search

Hemoglobinuria, Paroxysmalall three · compare here

Biogen in Hemoglobinuria, Paroxysmal: 1 program

  1. pegcetacoplanphase 3

Their studies: Biogen’s studies of Hemoglobinuria, Paroxysmal in search

Swedish Orphan Biovitrum in Hemoglobinuria, Paroxysmal: 1 program

  1. pegcetacoplanapproved, new study

Their studies: Swedish Orphan Biovitrum’s studies of Hemoglobinuria, Paroxysmal in search

AbbVie in Hemoglobinuria, Paroxysmal: 1 program

  1. pegcetacoplanphase 2

Their studies: AbbVie’s studies of Hemoglobinuria, Paroxysmal in search

Multiple Myeloma2 of 3 · compare here

Biogen in Multiple Myeloma: 1 program

  1. felzartamabphase 3

Their studies: Biogen’s studies of Multiple Myeloma in search

–
Psoriasis2 of 3 · compare here

Biogen in Psoriasis: 1 program

  1. Dimethyl Fumarateapproved, new study

Their studies: Biogen’s studies of Psoriasis in search

–

AbbVie in Psoriasis: 3 programs

  1. ABBV-295phase 2
  2. ABBV-547phase 2
  3. risankizumabapproved, new study

Their studies: AbbVie’s studies of Psoriasis in search

Breast Neoplasms2 of 3 · compare here

Biogen in Breast Neoplasms: 1 program

  1. omaveloxolonephase 3

Their studies: Biogen’s studies of Breast Neoplasms in search

–

AbbVie in Breast Neoplasms: 2 programs

  1. trifluridine tipiracil drug combinationphase 3
  2. RC148no phase

Their studies: AbbVie’s studies of Breast Neoplasms in search

Renal Insufficiency2 of 3 · compare here–

Swedish Orphan Biovitrum in Renal Insufficiency: 1 program

  1. AR882phase 3

Their studies: Swedish Orphan Biovitrum’s studies of Renal Insufficiency in search

AbbVie in Renal Insufficiency: 2 programs

  1. tavapadonphase 3
  2. emraclidinephase 2

Their studies: AbbVie’s studies of Renal Insufficiency in search

Arthritis, Juvenile2 of 3 · compare here–

Swedish Orphan Biovitrum in Arthritis, Juvenile: 1 program

  1. Interleukin 1 Receptor Antagonist Proteinapproved, new study

Their studies: Swedish Orphan Biovitrum’s studies of Arthritis, Juvenile in search

AbbVie in Arthritis, Juvenile: 1 program

  1. risankizumabapproved, new study

Their studies: AbbVie’s studies of Arthritis, Juvenile in search

Hematologic Neoplasms2 of 3 · compare here–

Swedish Orphan Biovitrum in Hematologic Neoplasms: 1 program

  1. pacritinibphase 3

Their studies: Swedish Orphan Biovitrum’s studies of Hematologic Neoplasms in search

AbbVie in Hematologic Neoplasms: 1 program

  1. BTK Degrader ABBV-101phase 1

Their studies: AbbVie’s studies of Hematologic Neoplasms in search

Show all 13

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: Biogen 5 of 11 · Swedish Orphan Biovitrum 5 of 7 · AbbVie 54 of 70 programs (23 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (AbbVie: 8).